Fetal tachycardia is at risk for developing low cardiac output, non-immune hydrops fetalis and ultimately fetal death. Sontaneous resolution of supraventricular tachycardia (SVT) is common in an infant during the first year of age, but some need long-term antiarrhythmic therapy. Including SVT in almost neonatal tachyarrhythmia, adenosine is the drug of the first choice. Digoxin is used to treat the SVT which is not controlled with adenosine. Class Ic and Class III antiarrhythmic drugs are recommended for the disease unresponsive to digoxin. Intravenous amiodarone is highly effective and safe in an infant with refractory or life threatening tachycardia. Some cases have been reported that amiodarone combined with digoxin therapy is effective. We report a case of a preterm infant born at 32weeks of gestational age with hydrops fetalis and life-threatening refractory SVT accompanied by multiple congenital heart diseases. SVT was initially not responsive to adenosine therapy and then successfully controlled with combination therapies of amiodarone and digoxin.